CTSB and glioblastoma: To evaluate the contribution of cathepsin activity in melanoma and glioblastoma cells, we employed a selective inhibitor targeting cathepsins B, L, and S. First, we assessed the cytotoxicity of the inhibitor on tumor cells by an MTT assay (Figure 8).